We are live on ! Find out more
EXEL icon

Exelixis

126 hedge funds and large institutions have $999M invested in Exelixis in 2013 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 46 increasing their positions, 32 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

115% more call options, than puts

Call options by funds: $5.42M | Put options by funds: $2.52M

100% more funds holding in top 10

Funds holding in top 10: 12 (+1)

70% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 10

44% more repeat investments, than reductions

Existing positions increased: 46 | Existing positions reduced: 32

42% more capital invested

Capital invested by funds: $702M → $999M (+$298M)

4% more funds holding

Funds holding: 121126 (+5)

Holders
126
Holders Change
+5
Holders Change %
+4.13%
% of All Funds
4.09%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.06%
New
17
Increased
46
Reduced
32
Closed
10
Calls
$5.42M
Puts
$2.52M
Net Calls
+$2.89M
Net Calls Change
+$2.09M

EXEL Hedge Fund Activity: Q3 2013 in Review

126 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in Exelixis (EXEL) for Q3 2013, worth a combined $999M — up 42% from $702M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new EXEL positions and 10 closed out — a net gain of 7 holders — while 46 added to existing stakes and 32 trimmed.

The largest buyer was OrbiMed, opening a new position worth an estimated $45.3M. The largest seller was T. Rowe Price Associates, cutting an estimated $3.95M.

  • 126 institutional investors held Exelixis (EXEL) as of Q3 2013, up from 121 in Q2 2013.
  • Funds reported $999M of Exelixis stock for Q3 2013, up 42% quarter-over-quarter.
  • 17 funds opened new Exelixis positions in Q3 2013 and 10 closed out, a net change of +7 holders.
  • The largest Exelixis buyer in Q3 2013 was OrbiMed, an estimated $45.3M added.
  • The largest Exelixis seller in Q3 2013 was T. Rowe Price Associates, an estimated $3.95M sold.

Based on aggregated 13F filings for Q3 2013.